CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
15 08 2019
15 08 2019
Historique:
received:
29
11
2018
accepted:
12
06
2019
pubmed:
3
7
2019
medline:
24
1
2020
entrez:
3
7
2019
Statut:
ppublish
Résumé
High-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) is the standard of care for relapsed or primary refractory (rel/ref) chemorefractory diffuse large B-cell lymphoma. Only 50% of patients are cured with this approach. We investigated safety and efficacy of CD19-specific chimeric antigen receptor (CAR) T cells administered following HDT-ASCT. Eligibility for this study includes poor-risk rel/ref aggressive B-cell non-Hodgkin lymphoma chemosensitive to salvage therapy with: (1) positron emission tomography-positive disease or (2) bone marrow involvement. Patients underwent standard HDT-ASCT followed by 19-28z CAR T cells on days +2 and +3. Of 15 subjects treated on study, dose-limiting toxicity was observed at both dose levels (5 × 10
Identifiants
pubmed: 31262783
pii: S0006-4971(20)46184-1
doi: 10.1182/blood.2018883421
pmc: PMC6695562
doi:
Substances chimiques
CD19-specific chimeric antigen receptor
0
Receptors, Antigen, T-Cell
0
Banques de données
ClinicalTrials.gov
['NCT01840566']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
626-635Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2019 by The American Society of Hematology.
Références
Nat Rev Cancer. 2012 Oct;12(10):671-84
pubmed: 22996603
J Clin Oncol. 1999 Apr;17(4):1244
pubmed: 10561185
Blood. 2016 Jul 28;128(4):519-28
pubmed: 27226436
Bone Marrow Transplant. 2016 Jan;51(1):51-7
pubmed: 26367239
Blood. 2013 Jan 24;121(4):573-84
pubmed: 23160470
Blood. 2015 Apr 16;125(16):2579-81
pubmed: 25758829
Sci Transl Med. 2016 Sep 7;8(355):355ra116
pubmed: 27605551
Sci Signal. 2018 Aug 21;11(544):
pubmed: 30131370
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
Cancer Cell. 2015 Oct 12;28(4):415-428
pubmed: 26461090
J Immunother. 2009 Feb-Mar;32(2):169-80
pubmed: 19238016
Blood. 2016 Jun 16;127(24):2980-90
pubmed: 27118452
J Clin Oncol. 2013 May 1;31(13):1662-8
pubmed: 23478060
J Clin Oncol. 2012 Dec 20;30(36):4462-9
pubmed: 23091101
Leukemia. 2017 May;31(5):1087-1095
pubmed: 28126984
Cancer Discov. 2015 Dec;5(12):1282-95
pubmed: 26516065
Blood. 2017 Oct 19;130(16):1800-1808
pubmed: 28774879
Br J Haematol. 2016 Nov;175(3):410-418
pubmed: 27378674
Immunol Rev. 2010 May;235(1):190-205
pubmed: 20536564
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
Blood. 2017 Jun 22;129(25):3322-3331
pubmed: 28408462
Mol Ther. 2017 Jan 4;25(1):285-295
pubmed: 28129122
J Clin Oncol. 2017 Sep 10;35(26):3010-3020
pubmed: 28715249
J Clin Invest. 2016 Sep 1;126(9):3363-76
pubmed: 27482888
J Clin Oncol. 2016 Apr 1;34(10):1112-21
pubmed: 26811520
Nat Biotechnol. 2002 Jan;20(1):70-5
pubmed: 11753365
Br J Haematol. 2010 Jul;150(1):39-45
pubmed: 20507301
Sci Transl Med. 2013 Mar 20;5(177):177ra38
pubmed: 23515080
Br J Haematol. 2013 Mar;160(5):608-17
pubmed: 23278720
Pharmacol Ther. 2017 Oct;178:83-91
pubmed: 28342824
J Clin Oncol. 2015 Feb 20;33(6):540-9
pubmed: 25154820
J Hematol Oncol. 2018 Mar 2;11(1):35
pubmed: 29499750
J Clin Oncol. 2010 Sep 20;28(27):4184-90
pubmed: 20660832
N Engl J Med. 1995 Dec 7;333(23):1540-5
pubmed: 7477169
Blood. 2012 Mar 15;119(11):2644-56
pubmed: 22138512
Leuk Lymphoma. 2012 Oct;53(10):1876-81
pubmed: 22432519
N Engl J Med. 2017 Dec 28;377(26):2545-2554
pubmed: 29226764
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Blood. 2012 Mar 22;119(12):2709-20
pubmed: 22160384
J Clin Invest. 2007 Feb;117(2):492-501
pubmed: 17273561
Cancer. 2008 Nov 1;113(9):2496-503
pubmed: 18833583
Blood. 2019 Feb 14;133(7):697-709
pubmed: 30463995
Cancer Discov. 2018 Aug;8(8):958-971
pubmed: 29880584
J Clin Oncol. 2008 Nov 10;26(32):5233-9
pubmed: 18809613
Biol Blood Marrow Transplant. 2007 Apr;13(4):486-92
pubmed: 17382255
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Cancer Immunol Res. 2016 Jun;4(6):498-508
pubmed: 27059623
J Clin Oncol. 2017 Jun 1;35(16):1803-1813
pubmed: 28291388